Securities & Exchang v. Maxxon, Inc.

CourtCourt of Appeals for the Tenth Circuit
DecidedOctober 11, 2006
Docket05-5091
StatusPublished

This text of Securities & Exchang v. Maxxon, Inc. (Securities & Exchang v. Maxxon, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Securities & Exchang v. Maxxon, Inc., (10th Cir. 2006).

Opinion

F I L E D United States Court of Appeals Tenth Circuit PU BL ISH October 11, 2006 UNITED STATES COURT O F APPEALS Elisabeth A. Shumaker Clerk of Court TENTH CIRCUIT

U N ITED STA TES SEC UR ITIES AND EX CH A NG E C OM M ISSIO N ,

Plaintiff - Appellee, v.

M AXXON, INC.; GIFFORD M . M ABIE, JR., No. 05-5091 Defendants - Appellants,

and

THOM AS R. COUGHLIN , JR.,

Defendant.

Appeal from the United States District Court for the N orthern District of Oklahom a (D.C. No. 4:02-CV-00975-TCK -SA J)

Ronald C. Kaufman, Kaufman & Associates, PLLC, Tulsa, OK (Jon B. W allis, Tulsa, OK, with him on the briefs), for Defendants - Appellants.

Susan S. M cDonald, Senior Litigation Counsel (Giovanni P. Prezioso, General Counsel, Eric Summergrad, Deputy Solicitor, and Susan Straus, Attorney, with her on the brief), Securities and Exchange Commission, W ashington, DC, for Plaintiff - Appellee.

Before L UC ER O, EBEL, and O’BRIEN, Circuit Judges. EBEL, Circuit Judge.

Defendants-Appellants Gifford M abie, Jr. and M axxon, Inc., the company

which M abie controls, appeal from a jury verdict finding them civilly liable for

violating various securities laws and a court judgment imposing various remedies.

Exercising jurisdiction under 28 U.S.C. § 1291, we AFFIRM . 1

BACKGROUND

M abie founded M axxon and served, at all relevant times, as its chief

executive officer. At the time this lawsuit was filed, he was the company’s sole

officer and director. Like other small companies with which M abie was

1 Although this was a complex case involving a ten-day jury trial and separate proceedings on remedies, the record on appeal contains few of the documents and motions filed below and only brief portions of the transcript of the relevant proceedings. Further, many of M axxon’s and M abie’s arguments consist of no more than unsupported statements that error occurred without any citation to pertinent legal authority. W e have endeavored to cull the record and interpret the arguments in order to address the issues on the merits wherever possible. However, we remind appellants of their obligation to support their arguments w ith legal authority, see, e.g., Rios v. Ziglar, 398 F.3d 1201, 1206 n.3 (10th Cir. 2005) (“To make a sufficient argument on appeal, a party must advance a reasoned argument . . . and it must support its argument with legal authority.”), and to provide a record sufficient to allow appellate review, see, e.g., 10th Cir. R. 10; Scott v. Hern, 216 F.3d 897, 912 (10th Cir. 2000) (“W here the record is insufficient to permit review we must affirm.”), or risk summary dismissal of their claims.

-2- connected, M axxon never paid him a salary but rather compensated him in shares

of stock. M abie often sold this stock to the public for a substantial profit.

M axxon was engaged in developing a “safety syringe”— a disposable

syringe with a retractable needle. Despite development attempts in conjunction

with several different partners, M axxon never put a m arketable syringe into

production. Even so, M abie made numerous statements promoting M axxon’s

product. For example, M abie claimed that M axxon’s syringe could be

manufactured for the same price as a standard syringe. Similarly, M abie stated

that the Swedish government was interested in building a facility to manufacture

its syringe. However, although a M axxon representative had met with the

Sw edish government, no statement of interest was made. M abie also stated that

major companies were interested in purchasing M axxon; in fact, those companies

had made clear that they would not be interested until M axxon had produced a

marketable syringe.

Of particular relevance to this appeal, on October 7, 1998, M axxon drafted

a press release stating that the Patterson Group, a health industry marketing firm,

had agreed to help it find a corporate buyer. The release was later issued to the

public, although no final agreement betw een the tw o parties was ever reached. In

addition, M abie stated that it had submitted an application to the FDA seeking

approval to manufacture the syringe. The statement failed to mention that the

-3- FD A had put its application on hold because M axxon had not provided sufficient

information. M axxon attempted to correct this information in mid-July, 2002.

The SEC brought the present lawsuit against M axxon and M abie, alleging

violations of the securities laws stemming from these statements. 2 The complaint

alleged, inter alia, that M axxon and M abie violated Section 10(b) of the Securities

Exchange Act of 1934; 3 SEC Rule 10b-5; 4 and Section 17(a)(1)-(3) of the

2 Thomas Coughlin, a medical advisor to M axxon, and Rhonda Vincent, M axxon’s financial reporting manager, were initially parties to the lawsuit as well. Vincent settled with the SEC, and Coughlin was found not liable by the jury. Neither are a party to the present appeal. 3 Section 10(b) provides:

It shall be unlawful for any person, directly or indirectly, by the use of any means or instrumentality of interstate commerce or of the mails, or of any facility of any national securities exchange . . . [t]o use or employ, in connection with the purchase or sale of any security registered on a national securities exchange or any security not so registered, or any securities-based sw ap agreement (as defined in section 206B of the Gramm-Leach-Bliley Act), any manipulative or deceptive device or contrivance in contravention of such rules and regulations as the Commission may prescribe as necessary or appropriate in the public interest or for the protection of investors.

15 U.S.C. § 78j(b). 4 Rule 10b-5 provides:

It shall be unlawful for any person, directly or indirectly, by the use of any means or instrumentality of interstate commerce, or of the mails or of any facility of any national securities exchange,

(a) To employ any device, scheme, or artifice to defraud,

(continued...)

-4- Securities Act of 1933. 5

At the outset of trial, M axxon and M abie filed a motion in limine to

exclude the report of W alter Rush, one of the SEC’s expert witnesses. Rush’s

role was to analyze M abie’s stock trades to calculate illegal profits. The motion

was denied, although the court ultimately ruled that Rush’s testimony before the

4 (...continued) (b) To make any untrue statem ent of a material fact or to omit to state a material fact necessary in order to make the statem ents m ade, in the light of the circumstances under which they were made, not misleading, or

(c) To engage in any act, practice, or course of business which operates or would operate as a fraud or deceit upon any person, in connection with the purchase or sale of any security.

17 C.F.R. § 240.10b-5. 5 Section 17(a), as amended, provides:

It shall be unlawful for any person in the offer or sale of any securities or any security-based swap agreement (as defined in section 206B of the Gramm-Leach-Bliley Act) by the use of any means or instruments of transportation or communication in interstate commerce or by use of the mails, directly or indirectly

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Securities & Exchange Commission v. Smyth
420 F.3d 1225 (Eleventh Circuit, 2005)
Goldberg v. Kelly
397 U.S. 254 (Supreme Court, 1970)
Geman v. Securities & Exchange Commission
334 F.3d 1183 (Tenth Circuit, 2003)
Rios v. Zigler
398 F.3d 1201 (Tenth Circuit, 2005)
United States v. Dazey
403 F.3d 1147 (Tenth Circuit, 2005)
Flying J Inc. v. Comdata Network, Inc.
405 F.3d 821 (Tenth Circuit, 2005)
Bowe v. Polymedica Corp.
432 F.3d 1 (First Circuit, 2005)
Roberts v. Galen of Virginia, Inc.
525 U.S. 249 (Supreme Court, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
Securities & Exchang v. Maxxon, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/securities-exchang-v-maxxon-inc-ca10-2006.